Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01902966 · ClinicalTrials.gov registry record · NA
Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)
A NA study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT01902966: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT01902966 is a NA study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01902966, a NA study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn how many patients with advanced, recurrent, incurable cervical cancer will complete questionnaires about symptoms, any anxiety, depression, and/or pain, and the quality of their lives. Researchers also want to learn how many of these patients will complete a study treatment of propranolol hydrochloride and relaxation and guided imagery sessions. Researchers also want to learn if and how propranolol hydrochloride and relaxation and guided imagery may affect cancer symptoms and any anxiety, depression, and/or pain, and quality of life. Propranolol hydrochloride is designed to block certain chemicals that affect the heart. Relaxation and guided imagery sessions are a form of relaxing meditation that involves tensing and relaxing various parts of your body from your feet to your head. In the guided imagery portion, you listen to recordings that are designed to help with calmness, control, and decreasing stress.
Interventions
- BEHAVIORAL Questionnaires
- DRUG Propranolol
- BEHAVIORAL Diary
- BEHAVIORAL Relaxation Audio Recording
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-09-11 |
| Est. Completion | 2020-08-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01902966
The ClinicalTrials.gov registry entry for NCT01902966 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Questionnaires is the first listed.
NCT01902966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01902966 about?
NCT01902966 is a clinical study titled "Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)". The goal of this clinical research study is to learn how many patients with advanced, recurrent, incurable cervical cancer will complete questionnaires about symptoms, any anxiety, depression, and/or pain, and the quality of their lives. Researchers also want to learn how many of these patients will...
What is the current status of trial NCT01902966?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2013-09-11. Estimated completion is 2020-08-14.
What interventions are being tested in trial NCT01902966?
The interventions under investigation include: Questionnaires (BEHAVIORAL), Propranolol (DRUG), Diary (BEHAVIORAL), Relaxation Audio Recording (BEHAVIORAL).
Who is sponsoring clinical trial NCT01902966?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.